Sign in
Already have access? Choose your edition
Sign-in is edition-specific. New here? Start with the free brief instead of jumping straight into a trial.
Each edition has its own app, pricing, and coverage page. Use sign-in if you already have access; otherwise pick an edition and get the free daily + weekly brief first.
AI
Daily briefings on AI labs, policy, tooling, and community shifts.
Best for
- Model releases + evals
- Policy and safety narratives
- Tooling and platform shifts
Featured signalUnlocked today
Canva has released its AI 2.0 update, introducing a unified conversational interface that allows users to create and edit designs using natural language prom...
Crypto
Daily briefings on markets, protocols, narratives, and risk events.
Best for
- Market structure + regulation
- Security and exploit narratives
- Protocol + dev ecosystem
Featured signalUnlocked today
Following a $280 million exploit on April 1, Drift Protocol has secured up to $148 million in funding from Tether and partners to support user fund recovery...
CYBERSECURITY
Daily briefings on vulnerabilities, incidents, and threat intel.
Best for
- Vulns and advisories
- Incidents + exploit narratives
- Vendor and community disclosures
Featured signalUnlocked today
Critical nginx-ui vulnerability CVE-2026-33032 enables full server takeover amid active exploitation
A critical authentication bypass vulnerability (CVE-2026-33032) in nginx-ui, an open-source web-based management tool for Nginx servers, is being actively ex...
ENERGY
Daily briefings on the energy transition: policy, grid, storage, and markets.
Best for
- Grid + reliability narratives
- Policy + first-party data
- Storage + transition supply chain
Featured signalUnlocked today
The ongoing Iran war is causing significant disruptions to energy and supply chains in Europe and the UK. The International Energy Agency warns Europe has on...
BIOTECH
Daily briefings on clinical, regulatory, and R&D updates from public sources.
Best for
- Clinical + regulatory narratives
- Research + preprints
- Funding + market updates
Featured signalUnlocked today
After the European Medicines Agency rejected Elevidys, Roche is launching another clinical trial to provide more robust data on the Duchenne muscular dystrop...